S
Silvia Crescioli
Researcher at King's College London
Publications - 47
Citations - 1424
Silvia Crescioli is an academic researcher from King's College London. The author has contributed to research in topics: Antibody & Immunoglobulin E. The author has an hindex of 14, co-authored 36 publications receiving 746 citations. Previous affiliations of Silvia Crescioli include Guy's Hospital & University of Florence.
Papers
More filters
Journal ArticleDOI
Antibodies to watch in 2022
TL;DR: The data show that, with antibodies for COVID-19 excluded, the late-stage commercial clinical pipeline of antibody therapeutics grew by over 30% in the past year, and marketing applications for at least 22 products may occur by the end of 2022.
Journal ArticleDOI
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma.
Duaa O. Khair,Heather J. Bax,Silvia Mele,Silvia Crescioli,Giulia Pellizzari,Atousa Khiabany,Mano Nakamura,Robert J. Harris,Elise French,Ricarda M. Hoffmann,Iwan P. Williams,Anthony Cheung,Benjamin Thair,Charlie T. Beales,Emma Touizer,Adrian W. Signell,Nahrin L. Tasnova,James Spicer,Debra H. Josephs,Jenny L. C. Geh,Alastair MacKenzie Ross,Ciaran Healy,Sophie Papa,Katie E. Lacy,Sophia N. Karagiannis +24 more
TL;DR: Results from pre-clinical studies and clinical trials indicate that novel agents, specific for checkpoints such as A2AR, LAG-3, IDO and others, may further contribute to the improvement of patient outcomes, most likely in combinations with anti-CTLA-4 or anti-PD-1 blockade.
Journal ArticleDOI
Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs).
Ricarda M. Hoffmann,Ben G T Coumbe,Ben G T Coumbe,Debra H. Josephs,Silvia Mele,Kristina M. Ilieva,Anthony Cheung,Andrew Tutt,James Spicer,David E. Thurston,David E. Thurston,Silvia Crescioli,Sophia N. Karagiannis +12 more
TL;DR: This work dissects the impact of Fab, linkers, isotype and Fc structure on the anti-tumoral and immune-activating functions of ADCs, highlighting novel design approaches informed by antibody structural attributes that may contribute to the success of next generation ADCs.
Journal ArticleDOI
Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.
Kristina M. Ilieva,Kristina M. Ilieva,Anthony Cheung,Anthony Cheung,Silvia Mele,Giulia Chiaruttini,Silvia Crescioli,Merope Griffin,Mano Nakamura,James Spicer,Sophia Tsoka,Katie E. Lacy,Andrew Tutt,Sophia N. Karagiannis,Sophia N. Karagiannis +14 more
TL;DR: This study reviews key potential anti-CSPG4 antibody and immune-based therapies and examines their direct antiproliferative/metastatic and immune activating mechanisms of action.
Journal ArticleDOI
BRAF inhibitors: resistance and the promise of combination treatments for melanoma
Merope Griffin,Daniele Scotto,Debra H. Josephs,Silvia Mele,Silvia Crescioli,Heather J. Bax,Giulia Pellizzari,Matthew D. Wynne,Mano Nakamura,Ricarda M. Hoffmann,Kristina M. Ilieva,Anthony Cheung,James Spicer,Sophie Papa,Katie E. Lacy,Sophia N. Karagiannis +15 more
TL;DR: This review focuses on numerous efforts to improve clinical benefits through combining agents with disparate modes of action, including combinations with checkpoint inhibitor antibodies and the merits of combination strategies based on enhancing immune responses or overcoming tumor-associated immune escape mechanisms.